| 05/22/2026 1:32 PM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/22/2026 11:29 AM | Novo Nordisk A/S (353278) Filer | Form SD Specialized Disclosure Report | |
| 05/22/2026 9:01 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/18/2026 9:29 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/13/2026 6:53 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/06/2026 6:51 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/05/2026 8:30 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/27/2026 6:21 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/20/2026 8:38 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/20/2026 5:50 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/13/2026 6:52 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Get the Latest News and Ratings for NVO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.
|
| 04/10/2026 7:30 AM | Innate Pharma SA (1598599) Subject Innate Pharma SA (1598599) Subject Novo Nordisk A/S (353278) Filed by | Form SCHEDULE 13G/A | |
| 04/07/2026 6:28 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/30/2026 8:05 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/27/2026 6:47 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/27/2026 5:33 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/26/2026 12:02 PM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/23/2026 7:56 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/20/2026 7:11 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/17/2026 6:10 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/09/2026 6:53 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/02/2026 10:47 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/02/2026 6:57 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/23/2026 7:19 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/23/2026 5:28 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/20/2026 6:45 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/17/2026 5:10 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/10/2026 5:16 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/09/2026 7:32 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/05/2026 1:54 PM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/05/2026 1:55 PM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/04/2026 8:28 AM | Novo Nordisk A/S (353278) Filer | Form IRANNOTICE | |
| 02/04/2026 8:23 AM | Novo Nordisk A/S (353278) Filer | Form 20-F Registration statement / Annual report / Transition report | |
| 02/04/2026 7:43 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/03/2026 11:29 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/03/2026 11:47 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/02/2026 11:43 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/02/2026 5:05 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/23/2025 8:56 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/25/2025 7:19 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/24/2025 6:23 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Porter flew 3,300 miles to investigate this system (Ad) Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film.
Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. Watch the full investigation and decide for yourself |
| 11/17/2025 2:35 PM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/14/2025 9:12 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/14/2025 5:00 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/12/2025 5:10 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/07/2025 5:00 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/05/2025 8:28 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/30/2025 6:38 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/21/2025 8:15 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/21/2025 8:16 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/21/2025 7:00 AM | Innate Pharma SA (1598599) Subject Innate Pharma SA (1598599) Subject Novo Nordisk A/S (353278) Filed by | Form SCHEDULE 13G/A | |
| 10/09/2025 6:37 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/10/2025 5:05 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/19/2025 7:35 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/14/2025 5:00 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/08/2025 8:34 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/08/2025 8:51 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/06/2025 6:23 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/04/2025 10:33 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/29/2025 7:21 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/29/2025 7:19 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/26/2025 6:35 PM | Novo Nordisk A/S (353278) Filer | Form 11-K Annual reports of employee stock purchase, savings and similar plans pursuant to Section 15(d) | |
| 06/26/2025 6:38 PM | Novo Nordisk A/S (353278) Filer | Form 11-K Annual reports of employee stock purchase, savings and similar plans pursuant to Section 15(d) | |
| 06/13/2025 6:11 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/30/2025 7:31 AM | Innate Pharma SA (1598599) Subject Innate Pharma SA (1598599) Subject Novo Nordisk A/S (353278) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/22/2025 5:41 AM | Novo Nordisk A/S (353278) Filer | Form SD Specialized Disclosure Report | |